# Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer

> **NCT03871205** · PHASE1 · UNKNOWN · sponsor: **Shenzhen People's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Carcinoma, Non-Small Cell Lung
- Carcinoma, Small Cell Lung

## Interventions

- **BIOLOGICAL:** Neoantigen loaded DC vaccine

## Key facts

- **NCT ID:** NCT03871205
- **Lead sponsor:** Shenzhen People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03871205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03871205, "Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03871205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*